Founded in the heart of Mirandola’s biomedical district, in just twenty-five years SIDAM managed to become a leader in the European biomedical sector thanks to major investments in research
By following up on and meeting the needs of hi-tech medical centres and of specialists in the biomedical sector, over the years the company has grown and expanded at the international level.
Today, we do business in 19 Countries throughout the world, and the export sector continues to be the engine that drives our growth.
We have overcome several challenges and went through some difficult times, such as the destruction caused by the earthquake that hit Mirandola in 2012, but we are now working double shifts in order to complete the many projects in which we are involved.
The company has won the 'Imprese X Innovazione - Andrea Pininfarina Award’, assigned by Confindustria for having successfully invested in research and innovation.
This is the first innovation award in Europe to have adopted the parameters of the European Foundation for Quality Management (EFQM) and participates, for the Industry and Services category, to the Prize of Prizes, an award set up by the President of the Council of Ministers on a mandate by the President of the Italian Republic.
We acquired a 75% stake in BTC Medical Europe, leader company in the postoperative blood recovery and oncology sectors and based in Valeggio sul Mincio (VR) and in Nonantola (MO).
The goal is to establish an entirely Italian biomedical centre and to enhance our portfolio of products and markets.
The European Radiology Congress - ECR 2017 (Wien, 1/5 march 2017) it’s the most important event in the continent, the second worldwide and Sidam can’t miss it. It’s a trend setting, dynamic environment where leading companies of the sector are taking the opportunity to discuss and present the latest technology progresses of the industry, with a particular focus on the newest generation of radiology professionals.
Another important milestone reached by Sidam: Mirandola's production site obtained from FDA (Food and Drug Administration) the Registration Number, which qualifies the company as a production workshop authorized to produce for the United States of America. This certification ensures, also for the North American market, the safety and efficacy of biomedical devices produced by the company, already recognized by the various awarding bodies responsible for Europe, South America and Asia. This recognition will allow Sidam to significantly expand its international business opportunities in the biomedical sector.